Arcutis Biotherapeutics Inc. (ARQT) Dividend Safety Gauge & 10-Year DRIP Compounder
Arcutis Biotherapeutics Inc. (ARQT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
$10,000 Compounded Over 10 Years → $40,809
Cash-Fortress Compounders: Collecting Safe Yield & Upside in ARQT & Top A-Rated Leaders
- ✓12-month Bull/Base/Bear fair-value walkthrough on ARQT and its top sector rival
- ✓The Top 5 Roarable A-Rated cash compounders with heavy executive & 13F accumulation
- ✓Includes free daily Morning Market Weather & signal upgrade/downgrade dispatch
ARQT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +91.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARQT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARQT. Explore sector supply chains on /butterfly.
ARQT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDDoes ARQT pay a dividend and is it safe?
Arcutis Biotherapeutics Inc. (ARQT) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.